Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

BAY 12-9566, a novel inhibitor of matrix metalloproteinases with antiangiogenic activity.

Gatto C, Rieppi M, Borsotti P, Innocenti S, Ceruti R, Drudis T, Scanziani E, Casazza AM, Taraboletti G, Giavazzi R.

Clin Cancer Res. 1999 Nov;5(11):3603-7.

2.

Naamidine A is an antagonist of the epidermal growth factor receptor and an in vivo active antitumor agent.

Copp BR, Fairchild CR, Cornell L, Casazza AM, Robinson S, Ireland CM.

J Med Chem. 1998 Sep 24;41(20):3909-11.

PMID:
9748366
3.

Eleutherobin, a novel cytotoxic agent that induces tubulin polymerization, is similar to paclitaxel (Taxol).

Long BH, Carboni JM, Wasserman AJ, Cornell LA, Casazza AM, Jensen PR, Lindel T, Fenical W, Fairchild CR.

Cancer Res. 1998 Mar 15;58(6):1111-5.

4.

Doxorubicin disaccharide analogue: apoptosis-related improvement of efficacy in vivo.

Arcamone F, Animati F, Berettoni M, Bigioni M, Capranico G, Casazza AM, Caserini C, Cipollone A, De Cesare M, Franciotti M, Lombardi P, Madami A, Manzini S, Monteagudo E, Polizzi D, Pratesi G, Righetti SC, Salvatore C, Supino R, Zunino F.

J Natl Cancer Inst. 1997 Aug 20;89(16):1217-23.

PMID:
9274917
5.

Preclinical antitumor activity of water-soluble paclitaxel derivatives.

Rose WC, Clark JL, Lee FY, Casazza AM.

Cancer Chemother Pharmacol. 1997;39(6):486-92.

PMID:
9118459
6.

Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates.

Trail PA, Willner D, Knipe J, Henderson AJ, Lasch SJ, Zoeckler ME, TrailSmith MD, Doyle TW, King HD, Casazza AM, Braslawsky GR, Brown J, Hofstead SJ, Greenfield RS, Firestone RA, Mosure K, Kadow KF, Yang MB, Hellström KE, Hellström I.

Cancer Res. 1997 Jan 1;57(1):100-5.

7.

Paclitaxel (Taxol(R)) inhibits motility of paclitaxel-resistant human ovarian carcinoma cells.

Belotti D, Rieppi M, Nicoletti MI, Casazza AM, Fojo T, Taraboletti G, Giavazzi R.

Clin Cancer Res. 1996 Oct;2(10):1725-30.

8.

Paclitaxel (Taxol): mechanisms of Resistance.

Casazza AM, Fairchild CR.

Cancer Treat Res. 1996;87:149-71. Review. No abstract available.

PMID:
8886452
9.

Drug immunotargeting for carcinomas: a reality at last?

Casazza AM, Trail PA, Hellström KE.

Ann Oncol. 1994 Oct;5(8):703-8. Review. No abstract available.

PMID:
7826902
10.

Reversal of the human and murine multidrug-resistance phenotype with megestrol acetate.

Wang L, Yang CP, Horwitz SB, Trail PA, Casazza AM.

Cancer Chemother Pharmacol. 1994;34(2):96-102.

PMID:
8194172
11.

Structure-activity relationships of VP-16 analogues.

Long BH, Casazza AM.

Cancer Chemother Pharmacol. 1994;34 Suppl:S26-31.

PMID:
8070024
12.

Screening methodologies for the discovery of novel cytotoxic antitumor agents.

Casazza AM, Long BH.

Biotechnology. 1994;26:281-300. Review. No abstract available.

PMID:
7749307
13.

Selective proteolytic activity of the antitumor agent kedarcidin.

Zein N, Casazza AM, Doyle TW, Leet JE, Schroeder DR, Solomon W, Nadler SG.

Proc Natl Acad Sci U S A. 1993 Sep 1;90(17):8009-12.

14.

Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates.

Trail PA, Willner D, Lasch SJ, Henderson AJ, Hofstead S, Casazza AM, Firestone RA, Hellström I, Hellström KE.

Science. 1993 Jul 9;261(5118):212-5. Erratum in: Science 1994 Feb 25;263(5150):1076.

PMID:
8327892
15.

Kedarcidin chromophore: an enediyne that cleaves DNA in a sequence-specific manner.

Zein N, Colson KL, Leet JE, Schroeder DR, Solomon W, Doyle TW, Casazza AM.

Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):2822-6.

16.

Preclinical antitumor activity of orally administered platinum (IV) complexes.

Rose WC, Crosswell AR, Schurig JE, Casazza AM.

Cancer Chemother Pharmacol. 1993;32(3):197-203.

PMID:
8500224
17.

Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines.

Long BH, Wang L, Lorico A, Wang RC, Brattain MG, Casazza AM.

Cancer Res. 1991 Oct 1;51(19):5275-83.

18.

Preclinical antitumor activity of a soluble etoposide analog, BMY-40481-30.

Rose WC, Basler GA, Trail PA, Saulnier M, Crosswell AR, Casazza AM.

Invest New Drugs. 1990;8 Suppl 1:S25-32.

PMID:
2380014
19.

Chemical and biological characterization of 4'-iodo-4'-deoxydoxorubicin.

Barbieri B, Giuliani FC, Bordoni T, Casazza AM, Geroni C, Bellini O, Suarato A, Gioia B, Penco S, Arcamone F.

Cancer Res. 1987 Aug 1;47(15):4001-6.

20.

Antitumor and toxicity evaluation of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes.

Rahman A, Fumagalli A, Barbieri B, Schein PS, Casazza AM.

Cancer Chemother Pharmacol. 1986;16(1):22-7.

PMID:
3940217
21.

Biochemical and biological activity of the anthracycline analog, 4-demethyl-6-O-methyl-doxorubicin.

Zunino F, Barbieri B, Bellini O, Casazza AM, Geroni C, Giuliani F, Ciana A, Manzini G, Quadrifoglio F.

Invest New Drugs. 1986;4(1):17-23.

PMID:
3700037
22.

Preclinical selection of new anthracyclines.

Casazza AM.

Cancer Treat Rep. 1986 Jan;70(1):43-9. Review. No abstract available.

PMID:
3510737
23.

New anthracycline glycosides obtained by the nitrous acid deamination of daunorubicin, doxorubicin and their configurational analogues.

Cassinelli G, Ballabio M, Arcamone F, Casazza AM, Podesta' A.

J Antibiot (Tokyo). 1985 Jul;38(7):856-67.

24.

13-Deoxycarminomycin, a new biosynthetic anthracycline.

Cassinelli G, Forenza S, Rivola G, Arcamone F, Grein A, Merli S, Casazza AM.

J Nat Prod. 1985 May-Jun;48(3):435-9.

PMID:
3861771
25.

Combined and sequential treatment using FCE 21336, a new prolactin-lowering drug, and medroxyprogesterone acetate (MPA) in DMBA-induced tumors in rats.

Zaccheo T, Casazza AM, di Salle E, Pollini C, di Marco A.

Eur J Cancer Clin Oncol. 1984 Sep;20(9):1193-7.

PMID:
6236980
26.

Synthesis, antitumor activity, and cardiac toxicity of new 4-demethoxyanthracyclines.

Penco S, Casazza AM, Franchi G, Barbieri B, Bellini O, Podestà A, Savi G, Pratesi G, Geroni C, Di Marco A, Arcamone F.

Cancer Treat Rep. 1983 Jul-Aug;67(7-8):665-73.

PMID:
6575865
27.

Antitumor activity in mice of 4'-deoxydoxorubicin in comparison with doxorubicin.

Casazza AM, Savi G, Pratesi G, Di Marco A.

Eur J Cancer Clin Oncol. 1983 Mar;19(3):411-8.

PMID:
6683178
28.

Synthesis, biological and biochemical properties of new anthracyclines modified in the aminosugar moiety.

Bargiotti A, Casazza AM, Cassinelli G, Di Marco A, Penco S, Pratesi G, Supino R, Zaccara A, Zunino F, Arcamone F.

Cancer Chemother Pharmacol. 1983;10(2):84-9.

PMID:
6831630
29.

New anthracycline glycosides: 4-O-demethyl-11-deoxydoxorubicin and analogues from Streptomyces peucetius var. aureus.

Cassinelli G, Rivola G, Ruggieri D, Arcamone F, Grein A, Merli S, Spalla C, Casazza AM, Di Marco A, Pratesi G.

J Antibiot (Tokyo). 1982 Feb;35(2):176-83.

30.

Effect of medroxyprogesterone acetate and doxorubicin on sublines of 13762 mammary adenocarcinoma in rats.

Formelli F, Zaccheo T, Casazza AM, Bellini O, Di Marco A.

Eur J Cancer Clin Oncol. 1981 Nov;17(11):1211-21. No abstract available.

PMID:
6460631
31.

Effect of the methylation of aglycone hydroxyl groups on the biological and biochemical properties of daunorubicin.

Zunino F, Casazza AM, Pratesi G, Formelli F, DiMarco A.

Biochem Pharmacol. 1981 Jul 1;30(13):1856-8. No abstract available.

PMID:
7271876
32.

Studies in mice treated with ICRF-159 combined with daunorubicin or doxorubicin.

Giuliani F, Casazza AM, Di Marco A, Savi G.

Cancer Treat Rep. 1981 Mar-Apr;65(3-4):267-76.

PMID:
6263470
33.

Cross resistance and cellular uptake of 4'-O-methyldoxorubicin in experimental tumors with acquired resistance to doxorubicin.

Di Marco A, Skovsgaard T, Casazza AM, Pratesi G, Nissen NI, Danø K.

Cancer Chemother Pharmacol. 1981;7(1):15-20.

PMID:
7340984
34.

Fluorescence assays and pharmacokinetic studies of 4'-deoxydoxorubicin and doxorubicin in organs of mice bearing solid tumors.

Formelli F, Pollini C, Casazza AM, di Marco A, Mariani A.

Cancer Chemother Pharmacol. 1981;5(3):139-44.

PMID:
7296751
35.

Evaluation of new anthracycline analogs with the human tumor stem cell assay.

Salmon SE, Liu RM, Casazza AM.

Cancer Chemother Pharmacol. 1981;6(2):103-9.

PMID:
6946877
36.

New anthracycline glycosides from Micromonospora. II. isolation, characterization and biological properties.

Cassinelli G, Di Matteo F, Forenza S, Ripamonti MC, Rivola G, Arcamone F, Di Marco A, Casazza AM, Soranzo C, Pratesi G.

J Antibiot (Tokyo). 1980 Dec;33(12):1468-73.

37.

Antileukemic activity of 4-demethoxydaunorubicin in mice.

Casazza AM, Pratesi G, Giuliani F, Di Marco A.

Tumori. 1980 Oct 31;66(5):549-64.

PMID:
6936969
38.

New antitumor drugs from plants.

Arcamone F, Cassinelli G, Casazza AM.

J Ethnopharmacol. 1980 Jun;2(2):149-60. No abstract available.

PMID:
7453201
39.

Combination chemotherapy and surgical adjuvant chemotherapy on MS-2 sarcoma and lung metastases in mice.

Giuliani F, Di Marco A, Casazza AM, Savi G.

Eur J Cancer. 1979 May;15(5):715-23. No abstract available.

PMID:
510334
40.

Preliminary phase I study of 4'-epi-adriamycin.

Bonfante V, Bonadonna G, Villani F, Di Fronzo G, Martini A, Casazza AM.

Cancer Treat Rep. 1979 May;63(5):915-8.

PMID:
455333
41.

Experimental evaluation of anthracycline analogs.

Casazza AM.

Cancer Treat Rep. 1979 May;63(5):835-44.

PMID:
455325
42.

Fluorescence assay of tissue distribution of 4-demethoxydaunorubicin and 4-demethoxydoxorubicin in mice bearing solid tumors.

Formelli F, Casazza AM, Di Marco A, Mariani A, Pollini C.

Cancer Chemother Pharmacol. 1979;3(4):261-9.

PMID:
294954
43.

Synthesis and antitumour activity of new daunorubicin and adriamycin analogues.

Arcamone F, Bernardi L, Patelli B, Giardino P, Di Marco A, Casazza AM, Soranzo C, Pratesi G.

Experientia. 1978 Oct 15;34(10):1255-7.

PMID:
570116
44.

Biologic characterization and chemotherapeutic response of MS-2 tumor: a non-regressing mouse sarcoma derived from MSV-M-induced sarcoma.

Giuliani F, Bellini O, Casazza AM, Formelli F, Savi G, Di Marco A.

Eur J Cancer. 1978 May;14(5):555-66. No abstract available.

PMID:
206445
45.

Enhancement of the antitumor activity of adriamycin by Tween 80.

Casazza AM, Pratesi G, Giuliani F, Formelli F, Di Marco A.

Tumori. 1978 Apr 30;64(2):115-29.

PMID:
675847
46.

Preparation and biological evaluation of 4-O-demethyldaunorubicin (carminomycin I) and of its 13-dihydro derivative.

Cassinelli G, Grein A, Masi P, Suarato A, Bernardi L, Arcamone F, Di Marco A, Casazza AM, Pratesi G, Soranzo C.

J Antibiot (Tokyo). 1978 Mar;31(3):178-84.

47.

Synthesis and antitumor activity of 4-demethoxyadriamycin and 4-demethoxy-4' -epiadriamycin.

Di Marco A, Casazza AM, Giuliani F, Pratesi G, Arcamone F, Bernardi L, Franchi G, Giardino P, Patelli B, Penco S.

Cancer Treat Rep. 1978 Mar;62(3):375-80.

PMID:
647696
48.

Effect of various substitutions in positions 1, 2, 3, and 4 of 4-demethoxydaunorubicin and 4-demethoxyadriamycin.

Di Marco A, Casazza AM, Soranzo C, Pratesi G.

Cancer Chemother Pharmacol. 1978;1(4):249-54.

PMID:
750112
49.

Antitumor activity of N-trifuloroacetyladriamycin-14-valerate.

Pratesi G, Casazza AM, Di Marco A.

Cancer Treat Rep. 1978 Jan;62(1):105-10.

PMID:
626988
50.

Comparison of biochemical and biological methods in the evaluation of new anthracycline drugs.

Di Marco A, Zunino F, Casazza AM.

Antibiot Chemother (1971). 1978;23:12-20. No abstract available.

PMID:
206196

Supplemental Content

Loading ...
Support Center